TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, 2-Period, Multicenter, Dble-Blind, Parallel-Group Study Comparing Effects of 2 Doses of MK0476 and Placebo in the Tx of Respiratory Symptoms Associated w/ Respiratory Syncytial Virus-Induced Bronchiolitis in Children 3 to 24 Mths
Brief Summary: The purpose of this study is to look at whether an investigational drug can treat the breathing symptoms of RSV bronchiolitis in children 3 to 24 months of age.


Options:
A: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): montelukast
B: Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo granules | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo granules; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease
Brief Summary: This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: GerEPO; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease
Brief Summary: This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
B: Arm Label: Erythropoiesis Stimulating Agents; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: Epoetin Beta, Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Methoxy Polyethylene Glycol-Epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta
C: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease
Brief Summary: This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: C.E.R.A.; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Arm Label: Darbepoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Intervention Type: DRUG; Name: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals; Assigned to Arm(s): C.E.R.A., Darbepoetin
B: Arm Label: C.E.R.A. 120, 200, or 360 mcg; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A. 120, 200, or 360 mcg
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
D: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease
Brief Summary: This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
C: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
B: Arm Label: Group 1 (Early Epoetin Beta); Type: EXPERIMENTAL; Interventions: Drug: Epoetin beta | Arm Label: Group 2 (No/Late Epoetin Beta); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Group 1 (Early Epoetin Beta), Group 2 (No/Late Epoetin Beta)
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: EPO rise; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: EPO stable; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin administration; Assigned to Arm(s): EPO rise, EPO stable

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Epoetin Hospira; Type: OTHER; Interventions: Biological: Epoetin Hospira Arm, Drug: IV Iron | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care Arm, Drug: IV Iron | Intervention Type: BIOLOGICAL; Name: Epoetin Hospira Arm; Assigned to Arm(s): Epoetin Hospira | Intervention Type: OTHER; Name: Standard of Care Arm; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Epoetin Hospira, Standard of Care
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
D: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Brief Summary: This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
C: Arm Label: C.E.R.A; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Epoetin Alfa
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
Brief Summary: The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.


Options:
A: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride
B: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
C: Arm Label: Quetiapine or Risperidone + Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + Aripiprazole | Arm Label: Quetiapine or Risperidone + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + placebo | Intervention Type: DRUG; Name: Quetiapine or Risperidone + Aripiprazole; Assigned to Arm(s): Quetiapine or Risperidone + Aripiprazole | Intervention Type: DRUG; Name: Quetiapine or Risperidone + placebo; Assigned to Arm(s): Quetiapine or Risperidone + placebo
D: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization
Brief Summary: Primary objective:

* To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd

Secondary objectives:

* To assess the reduction in mortality rate at the end of the double-blind treatment period, at 3 (90 ± 10 days) and at 6 (180 ± 10 days) months from the time of entry to the study, in patients on extended prophylaxis
* To assess the incidence of VTE at 3 months (90 ± 10 days) from the time of randomization to the study
* To evaluate the safety of extended enoxaparin VTE prophylaxis in acutely ill medical patients with prolonged immobilization. Safety evaluation includes:

  * Major and minor hemorrhage
  * Heparin induced thrombocytopenia
  * Serious adverse events
* To assess differences in levels of health-care utilization and cost between patients receiving extended VTE prophylaxis versus those receiving placebo.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
B: Arm Label: Heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Drug: Placebo | Arm Label: Nadroparin; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Heparin, Drug: Nadroparin | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin, Placebo | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Heparin, Nadroparin
C: Intervention Type: DRUG; Name: enoxaparin sodium; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization
Brief Summary: Primary objective:

* To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd

Secondary objectives:

* To assess the reduction in mortality rate at the end of the double-blind treatment period, at 3 (90 ± 10 days) and at 6 (180 ± 10 days) months from the time of entry to the study, in patients on extended prophylaxis
* To assess the incidence of VTE at 3 months (90 ± 10 days) from the time of randomization to the study
* To evaluate the safety of extended enoxaparin VTE prophylaxis in acutely ill medical patients with prolonged immobilization. Safety evaluation includes:

  * Major and minor hemorrhage
  * Heparin induced thrombocytopenia
  * Serious adverse events
* To assess differences in levels of health-care utilization and cost between patients receiving extended VTE prophylaxis versus those receiving placebo.


Options:
A: Intervention Type: DRUG; Name: enoxaparin sodium; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: A